Sign In
Buy SONN
$1.26
+0 (+0%)
At Close: Feb 27, 2026
Sonnet Announces Release of Corporate Update Video
04:15pm, Tuesday, 01'st Apr 2025
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targete
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.
07:30am, Tuesday, 01'st Apr 2025
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targete
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
09:05am, Wednesday, 26'th Mar 2025
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis ® ), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherap
Company advancing development of its modified version of Interleukin-18 (IL-18 Binding Protein Resistant or IL-18 BPR ) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with un
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
08:45am, Tuesday, 11'th Mar 2025
On-demand video webcast now available here
Poster presented at the 2025 AACR:IO Conference Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (F H AB ® )
Building on proven targeting of the F H AB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR)
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
09:15am, Tuesday, 18'th Feb 2025
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeu
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
08:30am, Thursday, 13'th Feb 2025
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
08:00am, Thursday, 13'th Feb 2025
Completion of SON-1010 (IL12-F H AB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, an
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteins
Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
08:35am, Wednesday, 22'nd Jan 2025
Live webcast on Wednesday, January 29 th at 2:40 PM ET PRINCETON, NJ, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clin
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
09:05am, Tuesday, 21'st Jan 2025
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis ® ) wit
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
09:20am, Monday, 23'rd Dec 2024
PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeuti
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
08:50am, Tuesday, 17'th Dec 2024
Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)
